



Vaccine Fact Sheet

MCV4

Brand Name and Manufacturer	Menactra® Sanofi Pasteur	Menveo® Novartis
Protects Against	Invasive Meningococcal Disease caused by Neisseria Meningitidis A, C, Y and W-135	Invasive Meningococcal Disease caused by Neisseria Meningitidis A, C, Y and W-135
Routine Schedule	One (1) dose at 11-12 years and one (1) booster dose at 16 years	One (1) dose at 11-12 years and one (1) booster dose at 16 years
Minimum Intervals	8 week minimum interval between doses	8 week minimum interval between doses
Approved for use in	Persons aged 9 months through 55 years	Persons aged 2 months through 55 years
Administration	Intramuscular (IM) injection	Intramuscular (IM) injection
Packaging	Vaccine is packaged as 5 single-dose 0.5mL vials	Vaccine is packaged as 5 single-dose 0.5mL vials of Men CYW-135 liquid component and 5 single-dose vials of lyophilized Men A component.
Storage	Refrigerate between 35°F and 46°F (2°C to 8°C) DO NOT FREEZE	Refrigerate between 35°F and 46°F (2°C to 8°C) PROTECT VACCINE FROM LIGHT DO NOT FREEZE
Full ACIP Recommendations	http://www.cdc.gov/mmwr/pdf/rr/rr6202.pdf	http://www.cdc.gov/mmwr/pdf/rr/rr6202.pdf http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6324a2.htm
VFC Letter	Not available on EZIZ	http://www.eziz.org/PDF/vfcletter_2010_05_Menveo-VaccineAvailable.pdf
Billing Codes	CHDP code: 69 CPT code for vaccine: 90734 CPT code for administration: 90460 Medi-Cal Fee-For-Service (FFS) administration: 90734-SL ICD-9-CM code: v03.89	CHDP code: 69 CPT code for vaccine: 90734 CPT code for administration: 90460 Medi-Cal Fee-For-Service (FFS) administration: 90734-SL ICD-9-CM code: v03.89
Comments	<ul style="list-style-type: none"> Licensed in 2005 2-dose primary series is recommended for certain high risk groups. See ACIP Recommendations Does not protect against Meningococcal serogroup B Boosters are recommended for those who remain at high risk. See ACIP Recommendations. If Menactra is given to children with functional or anatomic asplenia (including sickle cell disease), the PCV13 series should be completed first, and Menactra deferred until at least age 2 years. See ACIP Recommendations for details. 	<ul style="list-style-type: none"> Licensed in 2010 Does not protect against Meningococcal serogroup B Use only supplied (CYW) liquid component to reconstitute freeze dried component (A) Men CYW and Men A vials have separate lot numbers Providers should record lot number on the box. Number of doses for the primary series based on age and presence of certain high risk factor(s). See ACIP Recommendations. Boosters are recommended for those who remain at high risk. See ACIP Recommendations. Infants aged 2 through 23 months with functional or anatomic asplenia may receive MenACWY-CRM. MenACWY-CRM can be administered concomitantly with PCV13. See ACIP Recommendations for schedule.